MedPath

Lorazepam

Generic Name
Lorazepam
Brand Names
Ativan, Loreev
Drug Type
Small Molecule
Chemical Formula
C15H10Cl2N2O2
CAS Number
846-49-1
Unique Ingredient Identifier
O26FZP769L
Background

Lorazepam is a short-acting and rapidly cleared benzodiazepine used commonly as a sedative and anxiolytic. It was developed by DJ Richards, presented and marketed initially by Wyeth Pharmaceuticals in the USA in 1977. The first historic FDA label approval is reported in 1985 by the company Mutual Pharm.

Indication

Lorazepam is FDA-approved for the short-term relief of anxiety symptoms related to anxiety disorders and anxiety associated with depressive symptoms such as anxiety-associated insomnia. It is as well used as an anesthesia premedication in adults to relieve anxiety or to produce sedation/amnesia and for the treatment of status epilepticus.

Some off-label indications of lorazepam include rapid tranquilization of an agitated patient, alcohol withdrawal delirium, alcohol withdrawal syndrome, muscle spasms, insomnia, panic disorder, delirium, chemotherapy-associated anticipatory nausea and vomiting, and psychogenic catatonia.

Associated Conditions
Agitation, Alcohol Withdrawal Delirium, Alcohol Withdrawal Syndrome, Anxiety, Anxiety Disorders, Chemotherapy-Induced Nausea and Vomiting, Delirium, Insomnia, Muscle Spasms, Panic Disorder, Psychogenic Catatonia, Status Epilepticus
Associated Therapies
Anesthetic premedication therapy

Acute Effect of Three Neuroactive Drugs Measured by Magnetoencephalography (MEG), Electroencephalography (EEG) and the Synchronous Neural Interaction Test

Not Applicable
Completed
Conditions
Healthy
Interventions
First Posted Date
2009-09-09
Last Posted Date
2010-01-13
Lead Sponsor
Orasi Medical, Inc.
Target Recruit Count
15
Registration Number
NCT00972985
Locations
🇺🇸

Alexian Brothers Neuroscience Institute, Elk Grove Village, Illinois, United States

Study to Evaluate the Abuse Potential of AZD7325 in Healthy Recreational Central Nervous System (CNS) Depressant Users

Phase 1
Completed
Conditions
Recreational CNS Depressant Use
Interventions
First Posted Date
2009-05-15
Last Posted Date
2009-09-23
Lead Sponsor
AstraZeneca
Target Recruit Count
100
Registration Number
NCT00902772
Locations
🇨🇦

Research Site, Toronto, Ontario, Canada

Allogeneic Stem Cell Transplantation (ALLOSCT) in Recessive Dystrophic Epidermolysis Bullosa (RDEB)

Early Phase 1
Terminated
Conditions
Epidermolysis Bullosa
Interventions
First Posted Date
2009-04-15
Last Posted Date
2021-08-17
Lead Sponsor
Columbia University
Target Recruit Count
3
Registration Number
NCT00881556
Locations
🇺🇸

The Children's Hospital, Aurora, Colorado, United States

🇺🇸

Morgan Stanley Children's Hospital of NYP, New York, New York, United States

🇺🇸

Children's Memorial Hospital, Chicago, Illinois, United States

Effects of H1-Antagonist on Cognition

Not Applicable
Completed
Conditions
Cognition
Interventions
First Posted Date
2009-02-19
Last Posted Date
2009-02-19
Lead Sponsor
Maastricht University Medical Center
Target Recruit Count
18
Registration Number
NCT00846950
Locations
🇳🇱

Faculty of Psychology and Neuroscience, Maastricht University, Maastricht, Limburg, Netherlands

Proof of Concept in Patients With Generalized Anxiety Disorder (GAD)AZD7325

Phase 2
Completed
Conditions
Anxiety Disorders
Interventions
First Posted Date
2008-12-15
Last Posted Date
2010-10-08
Lead Sponsor
AstraZeneca
Target Recruit Count
369
Registration Number
NCT00807937
Locations
🇺🇸

Research Site, Seattle, Washington, United States

A Sedation/Cognition/EEG Study Using AZD6280 and Comparator

Phase 1
Completed
Conditions
Healthy Volunteer
Interventions
First Posted Date
2008-09-11
Last Posted Date
2009-06-26
Lead Sponsor
AstraZeneca
Target Recruit Count
17
Registration Number
NCT00750802
Locations
🇳🇱

Research Site, Leiden, Netherlands

Clinical Study in Healthy Volunteers to Investigate the Neurocognitive Effects of a New Antiepileptic Drug: Brivaracetam

Phase 1
Completed
Conditions
Epilepsy
Interventions
First Posted Date
2008-08-18
Last Posted Date
2012-05-28
Lead Sponsor
UCB Pharma
Target Recruit Count
20
Registration Number
NCT00736931

Nasal Versus Venous Lorazepam for Control of Acute Seizures in Children

Phase 3
Completed
Conditions
Status Epilepticus
Seizures
Interventions
First Posted Date
2008-08-15
Last Posted Date
2009-05-05
Lead Sponsor
All India Institute of Medical Sciences, New Delhi
Target Recruit Count
140
Registration Number
NCT00735527
Locations
🇮🇳

All India Institute of Medical Sciences, New Delhi, Delhi, India

A Sedation/Cognition/Electroencephalogram (EEG) Study Using AZD7325 and Comparator.

Phase 1
Completed
Conditions
Healthy Volunteer
Interventions
First Posted Date
2008-07-22
Last Posted Date
2010-12-10
Lead Sponsor
AstraZeneca
Target Recruit Count
16
Registration Number
NCT00720421
Locations
🇳🇱

Centre for Human Drug Research, Leiden, Netherlands

Clinical Study Assessing a New Scale to Measure Onset of Action in Generalized Anxiety Disorder

Not Applicable
Completed
Conditions
Anxiety Disorders
Interventions
First Posted Date
2008-07-15
Last Posted Date
2008-10-03
Lead Sponsor
Pfizer
Target Recruit Count
169
Registration Number
NCT00715039
Locations
🇺🇸

Pfizer Investigational Site, Cincinnati, Ohio, United States

© Copyright 2025. All Rights Reserved by MedPath